WFG Advisors LP Lowers Position in Eli Lilly and Company (LLY)

WFG Advisors LP lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 17.7% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 5,524 shares of the company’s stock after selling 1,189 shares during the period. WFG Advisors LP’s holdings in Eli Lilly and were worth $465,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. First Command Financial Services Inc. boosted its position in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares during the last quarter. Heritage Trust Co bought a new position in Eli Lilly and during the first quarter worth approximately $135,000. Penserra Capital Management LLC boosted its position in Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares during the last quarter. Crestwood Advisors Group LLC bought a new position in Eli Lilly and during the first quarter worth approximately $179,000. Finally, Sandy Spring Bank boosted its position in Eli Lilly and by 51.8% in the first quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock worth $185,000 after buying an additional 750 shares during the last quarter. 75.59% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company (NYSE:LLY) traded down 0.94% during mid-day trading on Friday, reaching $77.07. The company’s stock had a trading volume of 4,061,282 shares. The firm has a 50-day moving average of $82.39 and a 200 day moving average of $81.90. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72. The firm has a market capitalization of $81.31 billion, a price-to-earnings ratio of 33.35 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.86 earnings per share. Equities analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.70%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.

ILLEGAL ACTIVITY NOTICE: “WFG Advisors LP Lowers Position in Eli Lilly and Company (LLY)” was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.com-unik.info/2017/08/19/wfg-advisors-lp-reduces-stake-in-eli-lilly-and-company-lly-updated-updated.html.

A number of research firms have commented on LLY. BMO Capital Markets reaffirmed a “sell” rating and issued a $73.00 target price on shares of Eli Lilly and in a research report on Wednesday. Berenberg Bank reissued a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a research report on Friday, August 4th. TheStreet raised shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. UBS AG lowered shares of Eli Lilly and to a “hold” rating and set a $85.00 target price on the stock. in a research note on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. lowered shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 target price on the stock. in a research note on Wednesday, July 26th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $88.27.

In other news, insider Melissa S. Barnes sold 1,900 shares of the stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the transaction, the insider now owns 14,041 shares of the company’s stock, valued at approximately $1,134,231.98. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the sale, the insider now owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The disclosure for this sale can be found here. Insiders have sold 669,733 shares of company stock worth $55,845,287 over the last three months. 0.20% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit